Narrative review / 2007
Curcumin is safe up to 12 g/day in humans but exhibits poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination.
This review examines the bioavailability and pharmacologic properties of curcumin, a polyphenol derived from turmeric. Phase I clinical trials demonstrate that curcumin is safe even at high doses up to 12 g/day in humans, but it has poor bioavailability driven by poor absorption, rapid metabolism, and rapid systemic elimination. Approaches to enhance bioavailability include adjuvants like piperine, liposomal curcumin, nanoparticles, phospholipid complexes, and structural analogues such as EF-24. Despite low bioavailability, therapeutic efficacy has been documented against human diseases including cancer, cardiovascular diseases, diabetes, arthritis, neurological diseases, and Crohn's disease.
- Study type
- Narrative review
- Who was studied
- Humans in Phase I clinical trials
- What was measured
- Curcumin safety, bioavailability, and therapeutic efficacy
THE PAPER
Bioavailability of curcumin: problems and promises.
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Mol Pharm, 2007.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.